GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds

NCT ID: NCT02260609

Last Updated: 2016-02-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31

Brief Summary

A multicenter, open-label, single-arm study to evaluate the safety and efficacy of GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or bone.

Conditions

Complex Diabetic Foot Wounds

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open-Label

Grafix®: Cryopreserved Placental Membrane

Group Type: OTHER

Grafix®

Intervention Type: OTHER

The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.

Patients will be treated for up to 16 weeks.

Patients will be evaluated at screening and then weekly throughout the study or until wound closure.

Interventions

Grafix®

The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.

Patients will be treated for up to 16 weeks.

Patients will be evaluated at screening and then weekly throughout the study or until wound closure.

Intervention Type: OTHER

Other Intervention Names

Tissue; Allograft Tissue

Eligibility Criteria

Inclusion Criteria

1. Between 18 years and 85 years of age inclusive, as of the date of screening

2. Confirmed diagnosis of Type I or Type II Diabetes

3. Index wound graded in the Texas Classification System as Grade II-III, Stage A or C (without active infection)

4. Wound is located on the foot below the malleoli

5. Wound accommodates up to three (3) 5 cm x 5 cm pieces of GrafixCORE® that completely cover the wound

6. Patient's wound extends through the dermis and into subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule

7. Patient has adequate circulation to the foot as documented by either:

• Ankle Brachial Index (ABI) ≥ 0.5 and ≤ 1.2, or
• In patients with non-compressible ankle vessels, a Toe BP ≥ 40 mmHg or TcPO2 > 30 mmHg, or
• Skin perfusion pressure > 30 mmHg

Exclusion Criteria

1. Index Wound is of non-diabetic pathophysiology

2. Gangrene is present on any part of the affected foot

3. Index Wound is over a Charcot deformity

4. The longest dimension of the Index Wound exceeds 15 cm at the Baseline Visit

5. Patient has a glycated hemoglobin A1 (HbA1c) level of >14%

6. Requiring intravenous (IV) antibiotics to treat the index wound infection at enrollment

7. Patient has a wound within 15cm of the Index Ulcer identified for study consideration

8. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents

9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)

10. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or pus drainage from the wound site

11. Patient has active malignancy other than non-melanoma skin cancer

12. Patient's random blood sugar is >450 mg/dl at screening

13. Patient has untreated alcohol or substance abuse at the time of screening, or is deemed to be non-adherent to the protocol by the Investigator

14. Pregnant women

15. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening

16. Patient has allergy to primary or secondary dressing materials used in this trial

17. Patient has had within the last 14 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies

18. In the opinion of the Investigator, the patient is unsuitable for participation in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Osiris Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Miami VA

Miami, Florida, United States

South Shore Hospital

Weymouth, Massachusetts, United States

Carl T. Hayden Medical Research Foundation

Phoenix, Arizona, United States

Southern Arizona VA Health Care System

Tucson, Arizona, United States

Countries

United States

Other Identifiers

Osiris Protocol 310

Identifier Type: -

Identifier Source: org_study_id